CTPI-2

Overview

CTPI-2 is a third-generation mitochondrial citrate carrier SLC25A1 inhibitor with a K D of 3.5 μM. CTPI-2 inhibits glycolysis, PPARγ , and its downstream target the glucose transporter GLUT4 . CTPI-2 halts salient alterations of NASH reverting steatosis, preventing the evolution to steatohepatitis, reducing inflammatory macrophage infiltration in the liver and adipose tissue, and starkly mitigating obesity induced by a high-fat diet. Antitumor activity.

Application

Products | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Parkinson's Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Lung Cancer | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Mitochondrial Metabolism

Product Information

• Catalog No.: HY-123986
• CAS No.: 68003-38-3
• Molecular Formula: C13H9ClN2O6S
• Molecular Weight: 356.74
• Purity: 99.99%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
• Solubility: ≥ 2.08 mg/mL (5.83 mM); Clear solution
• Availability: In-stock

Source

Original product source